Lv7
4180 积分 2022-10-09 加入
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer
2小时前
待确认
Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma
12天前
已关闭
Response assessment criteria for brain metastases: proposal from the RANO group
14天前
已完结
Optimizing the safety of antibody-drug conjugates for patients with solid tumours
1个月前
已完结
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
2个月前
已完结
First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
3个月前
已完结
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
3个月前
已完结
Pneumonitis with combined immune checkpoint inhibitors and chemoradiotherapy in locally advanced non-small-cell lung cancer: a systematic review and meta-analysis
5个月前
已完结
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
5个月前
已完结
皖公网安备34019202002308
